3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Endocrine
1
Conditions
Breast Neoplasms
310
Neoplasm Metastasis
38
Neoplasms
22
Ovarian Neoplasms
18
Advanced Breast Cancer
18
Carcinoma, Non-Small-Cell Lung
14
Endometrial Neoplasms
11
Prostatic Neoplasms
10
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Colorectal Neoplasms
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Carcinoma, Ovarian Epithelial
5
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Breast Diseases
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Lobular
3
Uterine Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Interventions
Insulin Glargine
4
Insulin
3
volagidemab
2
Metformin
2
Fulvestrant
2
Alpelisib
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
DNA, Ribosomal
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Hyperglycemia
×
Fulvestrant
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts